President Donald Trump signed an executive order directing the U.S. Food and Drug Administration to fast-track review of psychedelics designated as breakthrough therapy drugs. [1]
The move could accelerate clinical trials for conditions such as depression, PTSD, and addiction, giving patients earlier access to treatments that are still under study. [3] The order arrives as lawmakers and health officials push for broader research into substances long restricted by federal policy.
The order directs the FDA to "expedite their review of certain psychedelics already designated as breakthrough therapy drugs," Trump said in a statement released to the media. [2] The language mirrors language in the administration’s broader push to reduce regulatory barriers for emerging therapies.
Reports differ on which compounds will receive the most attention. Marijuana Moment notes the order emphasizes research on psilocybin, the active ingredient in “magic mushrooms.” [3] An MSN article, however, highlights ibogaine as a drug the order could open to additional study. [2] The order itself does not name specific substances, instead focusing on any psychedelic that has earned breakthrough therapy status from the FDA.
If the FDA follows the order’s directive, the agency could shorten review timelines that currently span years, potentially bringing experimental therapies to patients within a few short years. [5] Advocates say faster review could help answer lingering questions about safety, dosage, and long-term effects, while critics warn that speed should not compromise rigorous evaluation.
The initiative reflects a shift from earlier administrations that largely maintained strict controls on psychedelic research. By leveraging the breakthrough therapy pathway—a designation reserved for drugs showing substantial improvement over existing treatments—the order seeks to align regulatory processes with scientific momentum.
**What this means**: The executive order signals a federal endorsement of psychedelic research, likely spurring increased funding and private sector investment. While the FDA’s actual pace will depend on resource allocation and scientific review, the order could shorten the path from laboratory to clinic for promising mental health therapies, reshaping how novel drugs are evaluated in the U.S.
“"directs the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs."”
The order creates a regulatory opening that may draw new research dollars and speed the clinical testing of psychedelics, potentially altering the treatment landscape for depression, PTSD, and other mental health disorders.
